Kazuomi Kario, ESC 2021 – the HERB Digital Therapeutics System and the HERB-DH1 Study
Prof. Kazuomi Kario (Professor, Jichi Medical University, Shimotsuke, Tochigi, Japan) kindly shared his thoughts on the HERB digital therapeutics system for essential hypertension and the HERB-DH1 study from the virtual ESC Congress 2021.
- Could you give us a brief overview of the HERB digital therapeutics system for essential hypertension? (0.14)
- What were the aims, design and inclusion criteria of the HERB-DH1 study? (1.29)
- What was the major outcome measured and how well were these achieved? (2.31)
- What were the limitations of the study? (4.08)
- What has this study taught us and what future studies are planned? (5.25)
- What do you think is the key takeaway for digital health technology? (6.35)
Speaker disclosures: Prof. Kazuomi Kario reports grants and personal fees from Omron Healthcare, Daiichi Sankyo, and Takeda Pharmaceutical; grants from A&D, Roche Diagnostics, Otsuka Holdings, Otsuka Pharmaceutical, Sanwa Kagaku Kenkyusho, Teijin Pharma, Fukuda Denshi and Fukuda Lifetec, and consulting fees from Terumo Co, Fukuda Denshi and Omron Healthcare. Prof Kario has also received consulting fees from CureApp Inc.
Support: Interview and filming supported by Touch Medical Media and conducted by Heather Hall.
Filmed during a remote video call with Professor Kazuomi Kario as a highlight of ESC 2021, August 2021.
Share this Video
Related Videos In Hypertension
Kelly Chin, ACC 2023: The treatment paradigm for patients with pulmonary arterial hypertension
Recommended therapy for patients with pulmonary arterial hypertension is generally a combination of an endothelin receptor antagonist and a phosphodiesterase type 5 inhibitor. In this touchCARDIO interview, we speak with Dr Kelly Chin (UT Southwestern Medical Centre, Dallas, TX, USA) to discuss the treatment paradigm. Dr Chin presented an abstract entitled ‘Efficacy And Safety Of […]
Kelly Chin, ACC 2023: A DUE phase III study, a macitentan and tadalafil combination for patients with pulmonary arterial hypertension
The aim of the A DUE study was to assess the combination of macitentan and tadalafil for patients with pulmonary arterial hypertension. In this touchCARDIO interview, we speak with Dr Kelly Chin (UT Southwestern Medical Centre, Dallas, TX, USA) to discuss the findings of the trial and the clinical impact. The abstract entitled ‘Efficacy And […]
Marius Hoeper, ACC 2023: STELLAR phase III trial results – Sotatercept for the treatment of pulmonary arterial hypertension
Pulmonary arterial hypertension (PAH) is a progressive disease involving proliferative remodeling of the pulmonary vessels and elevations in pulmonary vascular resistance (PVR). Despite recent treatment advances, the associated morbidity and mortality rates of the disease are still high. In this touchCARDIO interview, we speak with Prof. Marius Hoeper (Department of Respiratory Medicine, Hannover Medical School, Hannover, […]
Journal articles and more to your inbox
Get the latest clinical insights from touchCARDIOSign me up!